🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Evaluation of Knowledge on Tick-borne Encephalitis Virus (TBEV) Infection Among General Practitioners in France

Recruitingn/aAges 18 Years - anyAllUniversity Hospital, Strasbourg, France
NCT07191223 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Tick-borne encephalitis is a relatively rare disease (approximately 35 cases diagnosed per year), but most cases (86%) are due to contamination in France via a tick bite. Of the 71 cases reported over two years (May 2021 to May 2023), 94% of patients were hospitalized. It is therefore important to consider and diagnose at the first signs to ensure appropriate follow-up and also to implement primary prevention in endemic/at-risk areas.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Be a doctoral student or in training * Practice in France * Agree to participate in the survey. Exclusion Criteria: \- Refusal to participate in the study
💊

What it tests

  • Not listed
📍

Where

1 site
Service des maladies infectieuses et tropicales - CHU de Strasbourg - France
Strasbourg, France
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy